Holly Adams
Family · Athens, ALNPI 1215688916
Payments from drug & device makers
Across 128 payments — averaging $18.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$612
- AstraZeneca$352
- Otsuka America Pharmaceutical, Inc.$227
- Amgen$167
- Boehringer Ingelheim$142
- Lilly USA, LLC$134
- plus $770 from 15 others
What the payments were for
- Food & beverage$2,30496%
- Education$1004%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 37 | $612 |
| AstraZeneca | 14 | $352 |
| Otsuka America Pharmaceutical, Inc. | 15 | $227 |
| Amgen | 10 | $167 |
| Boehringer Ingelheim | 9 | $142 |
| Lilly USA, LLC | 6 | $134 |
| Novo Nordisk | 6 | $119 |
| Astellas Pharma US Inc | 2 | $115 |
| Bayer | 5 | $94 |
| Corcept Therapeutics | 4 | $78 |
| Corium, LLC | 5 | $73 |
| Idorsia Pharmaceuticals US Inc | 3 | $58 |
| Vanda Pharmaceuticals Inc. | 2 | $43 |
| Exact Sciences | 2 | $39 |
| Xeris Pharmaceuticals, Inc. | 2 | $29 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Lundbeck LLC | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Abbott | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$125
How this compares
$2,404 in reported general payments places this provider in the 80th percentile of 3,415 family providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 21 | $37,787 |
| EliquisApixaban | 29 | $22,598 |
| JardianceEmpagliflozin | 20 | $21,206 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $9,681 |
| FarxigaDapagliflozin Propanediol | 17 | $9,193 |
| TradjentaLinagliptin | 12 | $8,894 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $3,444 |
| Trazodone Hcl | 23 | $1,546 |
| Atorvastatin Calcium | 125 | $1,486 |
| Pantoprazole Sodium | 65 | $1,306 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 53 | $1,168 |
| Levothyroxine Sodium | 86 | $1,087 |
| Omeprazole | 68 | $992 |
| Celecoxib | 21 | $982 |
| Pravastatin Sodium | 48 | $959 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $119 | $37,78721 claims |
| Boehringer IngelheimJardiance, Tradjenta | $142 | $30,10032 claims |
| AstraZenecaFarxiga | $352 | $9,19317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,415 family providers in Alabama.
Other family in Athens
- Mona OliveAthens$20K
- Sara WoodAthens$18K
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Christopher LovellMobile$64K
- Justin SimpsonTuscaloosa$43K
- Kellyn McMahonBirmingham$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.